Dorothea is a senior Biotech leader and board member. Until recently, Dorothea served as Chief Technical Officer at Tigen Pharma, a startup in the field of autologous cell therapies. Under Dorothea’s guidance, Tigen was and is pioneering a distributed manufacturing model with the goal of reducing treatment costs and enhancing patient access.
Dorothea’s notable achievements include her time at Novartis, where she led manufacturing operations in Switzerland, Germany and Ireland. A highlight in her career was the build-up and operational launch of the first commercial Cell & Gene manufacturing facility for Novartis in Europe.
She is also serving at the Board of Directors of Cellaïon. The company is currently expecting results of a ph2 clinical trial with HepaStem®, an allogeneic off-the-shelf, liver-derived cell therapy that could become an alternative to liver transplantation.
Dorothea has a comprehensive understanding of the pharmaceutical industry, from research and development to manufacturing and supply chain management. She obtained her PhD from the University of the Saarland in Saarbrücken, Germany. She is a firm believer in cross-cultural and -functional teams to go beyond the beaten industry track.
Dorothea is currently preparing her next career step.